Erica N. Parker

Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens

Erica N. Parker, Bryon Drown, Emily J. Geddes et al. · Nature Microbiology · 2019 · 125 citations · Full text

Permeation Rules, Fabi Inhibitor, Health Sciences +13

An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with <i>In Vivo</i> Efficacy against Drug-Resistant Gram-Negative Infections

Erica N. Parker, Brett N. Cain, Behnoush Hajian et al. · ACS Central Science · 2022 · 71 citations · Full text

Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L

Erica N. Parker, Jiang-Li Song, G.D. Kishore Kumar et al. · Bioorganic & Medicinal Chemistry · 2015 · 33 citations · Full text

Cathepsin L, Biochemistry, Medicine +6

Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L

Gustavo E. Chavarria, Michael R. Horsman, Wara M. Arispe et al. · European Journal of Medicinal Chemistry · 2012 · 33 citations

Molecular Pharmacology, Medicinal Chemistry, Cathepsin L +12

Design and synthesis of bistereogenic chiral ionic liquids and their use as solvents for asymmetric Baylis–Hillman reactions

Satish Garre, Erica N. Parker, Bukuo Ni et al. · Organic & Biomolecular Chemistry · 2008 · 32 citations

Asymmetric Catalysis, Chemical Engineering, Chiral Centers +10